| Dr Derrick Cheung, MD | |
|
506 6th St, Brooklyn, NY 11215-3609 | |
| (646) 727-8279 | |
| Not Available |
| Full Name | Dr Derrick Cheung |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 17 Years |
| Location | 506 6th St, Brooklyn, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124274451 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | 280208 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Brookdale Hospital Medical Center | Brooklyn, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Brookdale Hospital Medical Center | 4284545799 | 279 |
News Archive
Pancreatic cancer kills more than 40,000 people every year, and among cancers it's particularly insidious. For 80 percent of patients, the disease is already so advanced at the time of diagnosis that treatment is unlikely to provide significantly life-extending benefits. For patients diagnosed with localized pancreatic cancer, the five-year survival rate remains barely above 20 percent, according to the National Cancer Institute.
Emerging Healthcare Solutions, Inc. announced today that the company has successfully completed the due diligence and review requirements under their recent option agreement with ThromboVision, a company that has licensed the patent on the new T-Guide® Platelet Function Analyzer, which is currently going through regulatory clearance review.
Researchers have successfully used a new and potentially safer method to stimulate ovulation in women undergoing IVF treatment.
The House Oversight and Government Reform Committee's Subcommittee on National Security and Foreign Affairs on Monday held a hearing to address concerns about quality of care and living conditions at the Walter Reed Army Medical Center, during which Army officials "acknowledg[ed] ... that they have failed in the care of wounded veterans," the Los Angeles Times reports.
Affomix Corporation, a pioneer in the development of automated, high-throughput monoclonal antibody selection technology, announced today that Kalgene Pharmaceuticals Inc. has signed a commercial agreement to have Affomix utilize its Y2HExpress™ technology to select antibodies with potential diagnostic and therapeutic utility in breast cancer. Kalgene Pharmaceuticals Inc. is a private company focused on the development of oncology therapeutics and companion diagnostics.
› Verified 4 days ago
| Entity Name | Brookdale Hospital Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720028772 PECOS PAC ID: 4284545799 Enrollment ID: O20031120000600 |
News Archive
Pancreatic cancer kills more than 40,000 people every year, and among cancers it's particularly insidious. For 80 percent of patients, the disease is already so advanced at the time of diagnosis that treatment is unlikely to provide significantly life-extending benefits. For patients diagnosed with localized pancreatic cancer, the five-year survival rate remains barely above 20 percent, according to the National Cancer Institute.
Emerging Healthcare Solutions, Inc. announced today that the company has successfully completed the due diligence and review requirements under their recent option agreement with ThromboVision, a company that has licensed the patent on the new T-Guide® Platelet Function Analyzer, which is currently going through regulatory clearance review.
Researchers have successfully used a new and potentially safer method to stimulate ovulation in women undergoing IVF treatment.
The House Oversight and Government Reform Committee's Subcommittee on National Security and Foreign Affairs on Monday held a hearing to address concerns about quality of care and living conditions at the Walter Reed Army Medical Center, during which Army officials "acknowledg[ed] ... that they have failed in the care of wounded veterans," the Los Angeles Times reports.
Affomix Corporation, a pioneer in the development of automated, high-throughput monoclonal antibody selection technology, announced today that Kalgene Pharmaceuticals Inc. has signed a commercial agreement to have Affomix utilize its Y2HExpress™ technology to select antibodies with potential diagnostic and therapeutic utility in breast cancer. Kalgene Pharmaceuticals Inc. is a private company focused on the development of oncology therapeutics and companion diagnostics.
› Verified 4 days ago
| Entity Name | Tbhc Physician Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417183963 PECOS PAC ID: 9133265317 Enrollment ID: O20091202000714 |
News Archive
Pancreatic cancer kills more than 40,000 people every year, and among cancers it's particularly insidious. For 80 percent of patients, the disease is already so advanced at the time of diagnosis that treatment is unlikely to provide significantly life-extending benefits. For patients diagnosed with localized pancreatic cancer, the five-year survival rate remains barely above 20 percent, according to the National Cancer Institute.
Emerging Healthcare Solutions, Inc. announced today that the company has successfully completed the due diligence and review requirements under their recent option agreement with ThromboVision, a company that has licensed the patent on the new T-Guide® Platelet Function Analyzer, which is currently going through regulatory clearance review.
Researchers have successfully used a new and potentially safer method to stimulate ovulation in women undergoing IVF treatment.
The House Oversight and Government Reform Committee's Subcommittee on National Security and Foreign Affairs on Monday held a hearing to address concerns about quality of care and living conditions at the Walter Reed Army Medical Center, during which Army officials "acknowledg[ed] ... that they have failed in the care of wounded veterans," the Los Angeles Times reports.
Affomix Corporation, a pioneer in the development of automated, high-throughput monoclonal antibody selection technology, announced today that Kalgene Pharmaceuticals Inc. has signed a commercial agreement to have Affomix utilize its Y2HExpress™ technology to select antibodies with potential diagnostic and therapeutic utility in breast cancer. Kalgene Pharmaceuticals Inc. is a private company focused on the development of oncology therapeutics and companion diagnostics.
› Verified 4 days ago
| Entity Name | Kingsbrook Medical Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104112838 PECOS PAC ID: 8729252028 Enrollment ID: O20111123000332 |
News Archive
Pancreatic cancer kills more than 40,000 people every year, and among cancers it's particularly insidious. For 80 percent of patients, the disease is already so advanced at the time of diagnosis that treatment is unlikely to provide significantly life-extending benefits. For patients diagnosed with localized pancreatic cancer, the five-year survival rate remains barely above 20 percent, according to the National Cancer Institute.
Emerging Healthcare Solutions, Inc. announced today that the company has successfully completed the due diligence and review requirements under their recent option agreement with ThromboVision, a company that has licensed the patent on the new T-Guide® Platelet Function Analyzer, which is currently going through regulatory clearance review.
Researchers have successfully used a new and potentially safer method to stimulate ovulation in women undergoing IVF treatment.
The House Oversight and Government Reform Committee's Subcommittee on National Security and Foreign Affairs on Monday held a hearing to address concerns about quality of care and living conditions at the Walter Reed Army Medical Center, during which Army officials "acknowledg[ed] ... that they have failed in the care of wounded veterans," the Los Angeles Times reports.
Affomix Corporation, a pioneer in the development of automated, high-throughput monoclonal antibody selection technology, announced today that Kalgene Pharmaceuticals Inc. has signed a commercial agreement to have Affomix utilize its Y2HExpress™ technology to select antibodies with potential diagnostic and therapeutic utility in breast cancer. Kalgene Pharmaceuticals Inc. is a private company focused on the development of oncology therapeutics and companion diagnostics.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Derrick Cheung, MD 506 6th St, Brooklyn, NY 11215-3609 Ph: (646) 727-8279 | Dr Derrick Cheung, MD 506 6th St, Brooklyn, NY 11215-3609 Ph: (646) 727-8279 |
News Archive
Pancreatic cancer kills more than 40,000 people every year, and among cancers it's particularly insidious. For 80 percent of patients, the disease is already so advanced at the time of diagnosis that treatment is unlikely to provide significantly life-extending benefits. For patients diagnosed with localized pancreatic cancer, the five-year survival rate remains barely above 20 percent, according to the National Cancer Institute.
Emerging Healthcare Solutions, Inc. announced today that the company has successfully completed the due diligence and review requirements under their recent option agreement with ThromboVision, a company that has licensed the patent on the new T-Guide® Platelet Function Analyzer, which is currently going through regulatory clearance review.
Researchers have successfully used a new and potentially safer method to stimulate ovulation in women undergoing IVF treatment.
The House Oversight and Government Reform Committee's Subcommittee on National Security and Foreign Affairs on Monday held a hearing to address concerns about quality of care and living conditions at the Walter Reed Army Medical Center, during which Army officials "acknowledg[ed] ... that they have failed in the care of wounded veterans," the Los Angeles Times reports.
Affomix Corporation, a pioneer in the development of automated, high-throughput monoclonal antibody selection technology, announced today that Kalgene Pharmaceuticals Inc. has signed a commercial agreement to have Affomix utilize its Y2HExpress™ technology to select antibodies with potential diagnostic and therapeutic utility in breast cancer. Kalgene Pharmaceuticals Inc. is a private company focused on the development of oncology therapeutics and companion diagnostics.
› Verified 4 days ago
Dr. Alexander Usorov, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 447 Atlantic Ave, Brooklyn, NY 11217 Phone: 718-858-6300 | |
Dr. Marcellus Andre Walker, MD Gastroenterology Medicare: May Accept Medicare Assignments Practice Location: 2094 Pitkin Ave, Brooklyn, NY 11207 Phone: 718-240-0516 Fax: 718-240-0564 | |
Lotus Ahmed, D.O Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 518 Mcdonald Ave, Brooklyn, NY 11218 Phone: 917-848-5432 Fax: 347-252-6754 | |
Mrs. Sophia Schwartzman, MD Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 2700 Ocean Avenue, Brooklyn, NY 11229 Phone: 518-587-1141 | |
Dr. Haitham M Ahmed, MD, MPH Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 101 Pennsylvania Avenue, Brooklyn, NY 11207 Phone: 718-240-2000 Fax: 718-240-2260 | |
Yanjin Yang, Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 506 6th St, Brooklyn, NY 11215 Phone: 718-780-3000 | |
Ashwad Afzal, M.D. Gastroenterology Medicare: Medicare Enrolled Practice Location: 506 6th St, Brooklyn, NY 11215 Phone: 718-780-5246 |